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Abstract
 Adults seeking diagnosis and treatment for tuberculosis (TB) andBackground:
HIV in low-resource settings face considerable barriers and have high
pre-treatment mortality. Efforts to improve access to prompt TB treatment have
been hampered by limitations in TB diagnostics, with considerable uncertainty
about how available and new tests can best be implemented.
The PROSPECT Study is an open, three-armDesign and methods: 
pragmatic randomised study that will investigate the effectiveness and
cost-effectiveness of optimised HIV and TB diagnosis and linkage to care
interventions in reducing time to TB diagnosis and prevalence of undiagnosed
TB and HIV in primary care in Blantyre, Malawi. Participants (≥ 18 years)
attending a primary care clinic with TB symptoms (cough of any duration) will
be randomly allocated to one of three groups: (i) standard of care; (ii) optimised
HIV diagnosis and linkage; or (iii) optimised HIV and TB diagnosis and linkage.
We will test two hypotheses: firstly, whether prompt linkage to HIV care should
be prioritised for adults with TB symptoms; and secondly, whether an optimised
TB triage testing algorithm comprised of digital chest x-ray evaluated by
computer-aided diagnosis software and sputum GeneXpert MTB/Rif can
outperform clinician-directed TB screening. The primary trial outcome will be
time to TB treatment initiation by day 56, and secondary outcomes will include
prevalence of undiagnosed TB and HIV, mortality, quality of life, and
cost-effectiveness.
 The PROSPECT Study will provide urgently-needed evidenceConclusions:
under “real-life” conditions to inform clinicians and policy makers on how best to
improve TB/HIV diagnosis and treatment in Africa.
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 improve TB/HIV diagnosis and treatment in Africa.
 (08/05/2018)Clinical trial registration: NCT03519425
Keywords
Tuberculosis, HIV, public health, screening, diagnostics, treatment, randomised
controlled trials, sub-Saharan Africa
 
This article is included in the Malawi-Liverpool
Wellcome Trust Clinical Research Programme
gateway.
 Peter MacPherson ( )Corresponding author: peter.macpherson@lstmed.ac.uk
  : Conceptualization, Methodology, Project Administration, Supervision, Writing – Original Draft Preparation, Writing –Author roles: MacPherson P
Review & Editing;  : Conceptualization, Methodology, Writing – Review & Editing;  : Conceptualization, Methodology,Webb EL Lalloo DG
Supervision, Writing – Review & Editing;  : Conceptualization, Resources, Writing – Review & Editing;  :Nliwasa M Maheswaran H
Conceptualization, Methodology, Writing – Review & Editing;  : Conceptualization, Methodology, Writing – Review & Editing;  :Joekes E Phiri D
Methodology, Writing – Review & Editing;  : Conceptualization, Methodology, Supervision, Writing – Review & Editing;  :Squire B Pai M
Conceptualization, Supervision, Writing – Review & Editing;  : Conceptualization, Funding Acquisition, Methodology, Supervision,Corbett EL
Writing – Review & Editing
 No competing interests were disclosed.Competing interests:
 MacPherson P, Webb EL, Lalloo DG   How to cite this article: et al. Design and protocol for a pragmatic randomised study to optimise
screening, prevention and care for tuberculosis and HIV in Malawi (PROSPECT Study) [version 1; referees: awaiting peer review]
Wellcome Open Research 2018,  :61 (doi:  )3 10.12688/wellcomeopenres.14598.1
 © 2018 MacPherson P  . This is an open access article distributed under the terms of the  ,Copyright: et al Creative Commons Attribution Licence
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
 This work was supported by the Wellcome Trust [206575 to PM, 200901 to ELC]. It was additional supported by the UKGrant information:
Medical Research Council (MRC) and the UK Department for International Development (DFID) under the MRC/DFID Concordat agreement
[MR/K012126/1] to ELW. ELW is also part of the EDCTP2 programme supported by the European Union. 
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
 18 May 2018,  :61 (doi:  ) First published: 3 10.12688/wellcomeopenres.14598.1
Page 2 of 14
Wellcome Open Research 2018, 3:61 Last updated: 18 MAY 2018
Introduction
Tuberculosis (TB) is now the leading infectious cause of death 
worldwide1. In 2016, there were an estimated 1.4 million deaths 
attributed to tuberculosis global, with an additional 0.4 million 
deaths from TB among people living with Human Immunode-
ficiency Virus (HIV) infection1,2. The countries of sub-Saharan 
Africa have been disproportionately affected by the HIV-TB 
co-epidemics. Following extremely rapid increases in TB inci-
dence, prevalence and deaths during the 1990s and 2000s in the 
region that occurred concurrently with rapid increases in popu-
lation HIV prevalence3, TB rates have only begun to decline 
in the region in recent years1. Although the expansion of cov-
erage of effective antiretroviral therapy (ART) for treatment 
of HIV in many sub-Saharan countries has likely contributed 
to recent reductions in mortality, the pace of decline is 
unacceptably slow.
New impetus has been given to efforts to improve tubercu-
losis control by the recent-agreed global End-TB Strategy4. 
This strategy, which was endorsed by WHO in 2015, demands 
global action and intensified research to address HIV-associated 
TB in 30-high HIV/TB burden countries that together comprise 
87% of the global burden of TB2. Key targets for the End-TB 
strategy include achievement by 2035 of a 90% reduction in TB 
incidence and a 95% reduction in TB mortality compared to 
20154.
Modelling studies have shown however that the End-TB targets 
will not be met without a step-change in efforts to improve the 
early diagnosis and effective treatment of all individuals with 
TB5. Of concern remains low population TB case detection 
rates, and high case-fatality ratios, particularly among people 
living with HIV6.
Adults seeking care at health facilities in sub-Saharan Africa 
are an important group to address in TB care and prevention 
programmes, as they have high prevalence of undiagnosed TB7, 
a substantial burden of undiagnosed and untreated HIV8, and 
high mortality rates if not promptly diagnosed and linked to 
treatment9.
Our previous studies - similar to research from other countries 
in sub-Saharan Africa - has shown that the patient pathway from 
first health centre attendance, through diagnosis to successful 
treatment outcome is tortuous, with high rates of drop-out 
from care8,10–12. Importantly, as well as having high mortality 
rates, individuals with symptoms of pulmonary TB who are not 
rapidly diagnosed may continue to transmit TB to others in the 
community, further limiting control efforts.
Although WHO guidelines promote intensified case-finding 
for TB among adults attending health facilities in high TB- 
prevalence settings13, implementation of routine screening for 
TB is known to be suboptimal in many settings. Exit interviews 
done with patients leaving health facilities has shown that clini-
cians rarely conduct an initial symptom screen14,15. Moreover, 
even when symptoms of presumptive TB are reported, only a 
small fraction receive appropriate investigations for TB14,15. Thus, 
even at the earliest step of the TB diagnostic and care pathway, 
there are high rates of loss from the cascade.
In addition to low rates of TB screening, we have previously 
shown that only a small proportion (13%) of adults attending 
health facilities receive HIV testing, despite WHO and Malawi 
guidelines recommending a strategy of universal provider- 
initiated HIV testing and counselling (HTC) for all individuals 
attending health centres, regardless of reason8. Uptake of HTC 
was highest among pregnant women attending for routine ante-
natal care, where considerable efforts have been undertaken to 
operationalise universal HTC as part of prevention of mother to 
child HIV transmission programmes. However, other groups, 
such as men and non-pregnant women have considerably lower 
rates of HIV testing completion8; as they are attending with 
an acute care episode and have a higher prevalence of active 
tuberculosis, they may have substantially worse outcomes 
compared to pregnant women.
Through systematic reviews, meta-analysis, and prospective 
cohort studies we have shown that even if patients attending 
health centres are diagnosed with TB or HIV, they face consid-
erable barriers to treatment initiation. In Africa, 18% of adults 
with sputum smear-positive tuberculosis will not initiate tubercu-
losis treatment promptly12, whilst only a fifth of HIV-diagnosed 
adults will remain in care continuously to initiation of ART10. 
Across both conditions a number of common factors hindering 
access to treatment have been identified, including: require-
ments to make multiple health centre visits for registration and 
assessment visits; debility; competing demands, including from 
work and education; and high out-of-pocket costs associated 
with visiting health centres16.
When both HIV and TB are suspected or diagnosed, patients 
can face even greater challenges. Despite repeated calls for 
integration of HIV and TB care and prevention services, most 
clinic services remain vertically-organised. This means that 
patients often required multiple health centre visits on differ-
ent days of the week to receive HIV and TB assessments and 
treatment, multiplying their adverse case-seeking costs and 
potentially worsening outcomes6,16.
We, and other, have therefore argued that new approaches are 
required to improve integration of HIV and TB screening, 
prevention and care services in health facilities in Africa that 
can provide same-day, same-clinic diagnosis and treatment 
linkage for both conditions at minimum inconvenience to 
patients16. Such an approach, if effective, is likely to have large 
benefits for patients, public health, and for health systems 
by improving case detection and treatment access, reducing 
mortality, and mitigating the catastrophic costs associated 
with care-seeking. However, strong evidence for effectiveness 
obtained through robust randomised controlled trials is currently 
lacking.
Current TB screening approaches are reliant upon diagnostic 
tests with considerable limitations.
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Sputum smear microscopy has been the mainstay of inves-
tigations for pulmonary tuberculosis for nearly a century. 
Although specificity is high, sensitivity remains unaccept-
ably low, especially among HIV-positive adults17,18. Moreover, 
as sputum smears must be prepared, fixed and examined under 
light or fluorescence microscopy, infection control, quality 
control, throughput, and achievement of same-day diagnosis are 
challenging.
TB culture of sputum is slow (3–8 weeks, even with auto-
mated liquid culture systems), and relies upon availability of a 
high-quality laboratory. These requirements mean that whilst 
culture has importance for individual management of complex 
cases and for monitoring and evaluation, it is not practical as a 
point of care test19.
GeneXpert MTB/Rif is an integrated and automated cartridge- 
based nucleic acid amplification test that can provide results 
for the detection of M tuberculosis and associated rifampicin 
resistance within two hours20. There are two components 
to the test: the cartridge in which the biological sample is 
added to the assay, and a standalone unit in which cartridge is 
placed and where the nucleic acid amplification and detection 
takes place. The sensitivity of the Xpert assay is substantially 
higher than sputum smear microscopy20, and the newest version 
(Xpert Ultra) shows pooled sensitivity (among HIV-positive 
and HIV negative samples) that is 5% higher than the first 
generation assay, with a 12% gain among HIV-positive adults. 
WHO has endorsed GeneXpert MTB/Rif as the first line 
test among adults suspected to have multidrug resistant TB or 
HIV-associated TB.
Despite these advantages, there are some barriers to the wide-
spread implementation of Xpert in low-resource, high TB preva-
lence settings. In particular, even at current concessional pricing 
for low-resource settings, Xpert is prohibitively expensive 
as a first line test for most national programmes.
Chest radiography has high sensitivity for pulmonary TB 
even in HIV coinfection21,22, and continues to play an impor-
tant role in TB diagnosis in high-income settings. Although 
chest x-ray has been used for many years as a diagnostic tool 
(usually at the end of screening algorithms), widespread imple-
mentation in high prevalence settings has been limited by poor 
access to high quality equipment and expert radiologists, low 
specificity (leading to over-diagnosis of TB if chest x-ray 
alone is used) and high inter-reader variability22. Recent 
advances in digital chest x-ray technologies have reinvigorated 
interest in the use of chest x-ray as an initial triage tool in 
primary care in Africa.
Chest X-ray may also be used as a triage test for TB22. In this 
triage approach, individuals with any abnormality identified 
on chest x-ray undergo confirmatory microbiological testing. 
Using a point-of-care high specificity molecular sputum testing 
for confirmatory testing (e.g. Xpert MTB/Rif) could allow 
accurate same-day TB diagnosis and treatment initiation in 
primary care.
In December 2016, WHO released a new evidence review 
and guidance22 for chest x-ray TB triage that used data from 
systematic review to model the potential effectiveness of 
TB screening algorithms, and showed that triage using chest 
x-ray, followed by GeneXpert MTB/Rif could substantially 
outperform other approaches.
Currently, countries such as Malawi have low coverage of radiol-
ogy services, including trained radiologists. Computer-assisted 
detection (CAD) software - statistical algorithms used to classify 
digital images - is now available, and can be integrated within 
new digital x-ray units to provide immediate triage23. WHO 
recently systematically reviewed available evidence for one 
CAD system (CAD4TB, Delft Imaging Systems, Netherlands). 
Across 13 studies conducted in a variety of populations, 
sensitivity was as high as reading by radiologists, although 
specificity was lower necessitating microbiological confirma-
tion of TB22. Whilst promising, WHO recommends that “CAD 
can be used for TB detection for research, ideally following a 
protocol that contributes to the required evidence base for 
guideline development”22.
In summary, adults with symptoms of tuberculosis in Malawi 
face considerable health systems delays, large out-of-pocket 
expenses, and have a high risk of mortality before diagnosis 
and treatment. To achieve the End-TB Strategy goals, a pack-
age of same-day, same-clinic diagnosis and treatment linkage 
interventions for both TB and HIV are urgently required. In an 
individually-randomised, open, three-arm controlled trial, The 
PROSPECT Study will investigate whether optimised TB and 
HIV diagnosis and treatment linkage interventions are cost- 
effective in reducing time to TB treatment initiation, and in 
improving case detection.
Methods
Study design
The PROPSECT Study is an open, three-arm pragmatic ran-
domised controlled trial.
Study hypothesis
The PROSPECT Study will test the hypothesis that an optimised 
same-day TB/HIV screening and treatment linkage interven-
tion for adults with presumptive tuberculosis in primary care 
could result in important improvements in case detection, 
treatment initiation and mortality.
Objectives
I.     Among adults with TB symptoms attending primary 
care in Malawi, to investigate the effectiveness of an 
optimised same-day screening algorithm consisting of 
rapid HIV testing, computer-assisted CAD4TB chest x-ray 
triage and, if abnormal, Xpert MTB/Rif rapid sputum 
molecular testing, and linkage to treatment.
II.    In a nested diagnostic accuracy study evaluate the sen-
sitivity and specificity of computer-assisted chest 
x-ray triage compared to classification by radiologists and 
bacteriological diagnosis.
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III.    Undertake a cost-utility analysis of the PROSPECT 
interventions to estimate the incremental cost per QALY 
gained from providing optimised TB and HIV diagnosis 
and linkage to care.
Study site and population
The study will be done at Bangwe Health Centre, a busy health 
centre located in a densely populated urban neighbourhood 
of Blantyre, Malawi. Adult prevalence of tuberculosis and 
HIV in Blantyre are >900 per 100,00024 and 18.5% respectively25.
TB diagnostics available at the study clinic include sputum 
smear fluorescence microscopy with LED microscopes, and 
Xpert MTB/Rif. Although Malawi and World Health Organisa-
tion (WHO) guidelines recommend screening for tuberculosis for 
all individuals attending health facilities with acute illness (with 
Xpert preferred as the first-line investigation for symptomatic 
HIV-positive individuals), our previous research shows that TB 
diagnostics are underutilised26.
At the study clinic, comprehensive HIV care is available and 
includes: routine provider-initiated HIV testing and coun-
selling, screening and treatment of opportunistic infections, 
provision of chemoprophylaxis, and treatment with antiretrovi-
ral therapy. Malawi National Guidelines have recommended a 
“test and treat” approach to HIV since 2015, with all individu-
als diagnosed with HIV being eligible for antiretroviral therapy. 
Our previous research has shown however that coverage of 
HIV testing and rates of linkage to antiretroviral therapy are 
suboptimal8,10, as in many other African settings.
Study participants will be adults aged 18 years or older who 
attend Bangwe Health Centre for acute care with symptoms of 
tuberculosis (cough of any duration). As this is a pragmatic ran-
domised trial that aims to provide evidence for policymakers 
under “real-life” conditions, eligibility criteria will be broad, and 
will reflect the characteristics of adults attending primary health 
centres in Southern Africa to maximise generalisability. We will 
exclude: individuals who are taking treatment for tuberculosis, 
or who have taken tuberculosis treatment in the preceding 
6-months; individuals taking isoniazid preventive therapy; and 
individuals who live outside of Blantyre or plan to relocate 
outside of Blantyre in the next six months.
Research assistants based at the clinic registration desk will 
screen all daily attenders against eligibility criteria. As individu-
als may attend the clinic on more than one occasion during the 
study period, the research assistant will record a digital finger-
print (Simprints, Cambridge, UK) from all clinic attenders to 
ensure that repeat clinic attendance episodes are recorded and so 
removing the potential for duplication in trial recruitment.
Randomisation and blinding
Participants will be individually randomly allocated in a 1:1:1 
ratio into one of three groups.
Randomisation will be done by research assistants using a ran-
dom number allocation schedule running on study data-collection 
electronic tablets. Because of the nature of the study and the 
interventions offered, it will not be possible to blind participants 
or research assistants to allocation groups. Nevertheless, exten-
sive steps will be taken to ensure that research assistants 
undertaking outcome assessments are blinded to participants’ 
group. Additionally, the investigators, including the chief inves-
tigator and trial statistician, will remain blinded to allocation 
groups until final analysis. No unblinded interim analysis will 
be conducted.
Interventions
All participants
All participants will complete a baseline questionnaire 
(Supplementary File 1), that will record demographic and 
clinical characteristics (including previous HIV and TB care), 
as well as geolocation information16 to facilitate home tracing if 
participants don’t attend for outcomes assessments. All partici-
pants will additionally complete the EuroQoL EQ5D (Chichewa) 
tool (English version validated for the UK available here) to 
measure health-related quality of life.
Group 1: Standard of care
Interventions available to participants allocated to Group 1 
are intended to mirror the current standard of care for HIV 
and TB screening and linkage to care under routine condi-
tions in primary care in Malawi (Figure 1). This will ensure that 
the incremental cost-effectiveness of interventions offered in 
Groups 2 and 3 can be compared to a standard care that reflects 
“real-life” practice.
Participants allocated to Group 1 will be directed to the 
routine facility waiting area to be seen by facility health work-
ers. Screening for HIV and tuberculosis will be directed by 
the routine facility health workers in accordance with Malawi 
National Guidelines, and without any further trial interventions.
Group 2: Optimised HIV screening and linkage to care
Participants allocated to Group 2 will be offered a supervised 
HIV self-testing intervention using oral fluid rapid diagnostic 
kits (OraQuick® HIV-1/2 rapid antibody test kits, manufactured 
in Thailand for: OraSure Technologies, Inc. Bethlehem, PA, 
USA). Participants will have their identity validated by finger-
print scanning, will be provided with brief pre-test counselling 
and instruction and demonstration in the use of the oral fluid 
kits by research assistants, and will be asked to self-test 
in a private clinic area, with support from the research assistant.
Participants who test HIV-negative will be referred to the 
clinic waiting area with a copy of their HIV test result, and will 
be assessed by the routine facility health workers as in Group 1.
Participants whose oral fluid test is reactive will have con-
firmatory HIV testing performed by trained research assistants 
using rapid diagnostic kits and following a testing algorithm 
as recommended by WHO and Malawi National Guidelines.
Participants with confirmed HIV infection will be supported to 
register for HIV care at the HIV care clinic located within the 
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Figure 1. PROSPECT Trial Design. WHO: World Health Organization, TB: tuberculosis, HIV: Human immunodeficiency virus, +ve: positive, 
-ve: negative, ART: antiretroviral therapy, Rx: treatment, +/- : with, or without.
study health centre and will be provided with a written appoint-
ment date to attend for initial antiretroviral therapy assessment 
and initiation appointment. As part of HIV treatment assess-
ments, Malawi National guidelines recommend screening 
for active tuberculosis. In this group, participants’ TB screening 
will be directed by facility HIV clinic healthworkers - not 
by the study team - with sputum smear microscopy and 
GeneXpert MTB/Rif available to clinicians through routine 
clinic services, and without further study intervention.
Group 3: Optimised TB and HIV screening and linkage to care
Participants allocated to Group 3 will be directed to a research 
study room located in a separate area of the clinic. Prior to 
intervention delivery, a digital fingerprint check will be repeated 
to validate participants’ identity and minimise any potential 
for contamination between groups. Participants will be offered 
supervised HIV self-testing, with confirmatory testing and 
post-test counselling as in Group 2 above.
All participants allocated to Group 3 will additionally be offered 
a digital chest x-ray (MinXray Inc., USA) that will be pre- 
processed and quality-checked by a study radiographer. Digital 
chest x-ray images will then be immediately evaluated by the 
CAD4TB computer-aided TB triage algorithm (Delpht Imaging 
Systems, Netherlands). Application of the CAD algorithm 
will provide a TB score ranging from 0 to 100. We will 
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select a threshold designed to optimise sensitivity based on 
our previous research and validation studies in this population. 
Participants with a CAD score at or above this threshold will 
be classified as having “high probability of tuberculosis”, 
whilst those below this threshold will be classified as having 
“low probability of TB”.
Participants whose chest x-rays are classified as having “high 
probability of TB” will be invited to submit a single sputum 
sample (induced with saline nebulization if necessary) for testing 
by GeneXpert MTB/Rif (Cephaid, USA) in the study clinic. 
Participants whose GeneXpert MTB/Rif results demonstrate 
the presence of M. tuberculosis will be supported to register for 
tuberculosis treatment on the same day at the TB clinic within 
the study health facility.
Participants whose chest x-ray are classified as being “low 
probability of TB” and those whose GeneXpert MTB/Rif tests 
are negative will be referred to the clinic waiting room to be 
seen by facility healthworkers, with a written report of the 
results of the investigations they have completed.
Definitions
Microbiologically-confirmed tuberculosis will be defined by: 
A participant with: a documented positive GeneXpert MTB/
Rif result for Mycobacterium tuberculosis on at least one 
sample of sputum taken for study or routine clinical purposes; 
or documented growth of Mycobacterium tuberculosis and 
positive speciation using MPT 64 antigen tests on at least one 
culture of sputum taken for study or routine clinical purposes; 
or documented identification of acid fast bacilli on at least one 
sputum sample taken for study or routine clinical purposes 
and examined by sputum smear microscopy.
Clinically-diagnosed tuberculosis will be defined by: A 
participant who does not fulfil the criteria for microbiologi-
cally-confirmed TB but has documented evidence of having 
been diagnosed with active TB by a clinician or other medical 
practitioner who has decided to give the patient a full course 
of TB treatment. This definition includes cases diagnosed on 
the basis of X-ray abnormalities or suggestive histology and 
extrapulmonary cases without laboratory confirmation. Clinically- 
diagnosed cases that are subsequently found to be bacterio-
logically-positive (before or after starting treatment) will be 
reclassified as bacteriologically-confirmed.
Pulmonary tuberculosis (PTB) will be defined by: 
A participant with bacteriologically-confirmed or clinically 
diagnosed case of TB involving the lung parenchyma or the 
tracheobronchial tree. Miliary TB will be classified as PTB 
because there are lesions in the lungs. Tuberculous intra- 
thoracic lymphadenopathy (mediastinal and/or hilar) or tubercu-
lous pleural effusion, without radiographic abnormalities in the 
lungs, constitutes a case of extrapulmonary TB. A patient with 
both pulmonary and extrapulmonary TB will be classified as 
a case of PTB.
Extrapulmonary tuberculosis (EPTB) will be defined by: A par-
ticipant with bacteriologically-confirmed or clinically-diagnosed 
case of TB involving organs other than the lungs, e.g. pleura, 
lymph nodes, abdomen, genitourinary tract, skin, joints and bones, 
meninges.
Initiation of tuberculosis treatment will be defined by: A 
participant in whom there is documented evidence of com-
mencement of anti-tuberculosis treatment, either by: inspection 
of the participant-carried national tuberculosis treatment card; 
or inspection of the facility tuberculosis treatment register; 
or inspection of TB treatment medication bottles or pill boxes.
Initiation of antiretroviral therapy will be defined by: A 
participant in whom there is documented evidence of commence-
ment of combination antiretroviral therapy treatment, either by: 
inspection of the participant-carried national HIV programme 
treatment card; or inspection of the facility antiretroviral 
therapy treatment register; or inspection of antiretroviral therapy 
medication bottles or pill boxes.
Successful tuberculosis treatment outcome will be defined 
by: A participant in whom tuberculosis treatment is initiated for 
bacteriologically-confirmed pulmonary tuberculosis, and who 
has documented evidence in their national tuberculosis treatment 
card of being cured of TB, being either sputum smear- or cul-
ture-negative in their last month of treatment and on at least 
one previous occasion; or a participant with documented 
evidence of having completed TB treatment without evidence 
of failure (that is sputum smear- or culture-positive at month 5 
or later during treatment) but with no record to show that 
sputum smear or culture results in the last month of treat-
ment and on at least one previous occasion were negative, 
either because tests were not done or because results are 
unavailable.
Adverse events
As this is a pragmatic randomised trial and no new investi-
gational products are being evaluated, we anticipate only a 
small number of adverse events. Nevertheless, we will ensure 
that case definitions, standardised operating procedures and a 
reporting protocol will be in place to record all adverse events.
The following adverse events will be systematically recorded 
and reported:
•    Misclassification or misinterpretation of results leading 
to a participant starting TB therapy in error
•    Misclassification or misinterpretation of results leading 
to a participant starting HIV treatment in error
•    Breach of confidentiality following TB or HIV diagnosis
•    Needlestick injuries
Trial outcomes
The primary trial outcome will be time in days – from Day 
0 up to but not including Day 56 – to tuberculosis treatment 
initiation, evaluated at Day 56 following randomization.
Analysis of the primary outcome will be done on an intention 
to treat basis, with all participants allocated to trial groups 
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included and analysed in the group to which they were 
randomized (regardless of which intervention was received). We 
will make three pair-wise comparisons (Group 2 vs. Group 1; 
Group 3 vs. Group 2; and Group 3 vs. Group 1).
This primary endpoint has been chosen because reducing time 
to initiation of treatment could have important individual and 
public health benefits. Assessment over eight weeks has been 
selected because: (i) TB culture is typically completed within 
8 weeks, (ii) mortality is highest during this period27,28, and 
(iii) previous trials and our previous research show that TB 
treatment initiations plateau by 8 weeks27.
The secondary trial outcomes will be:
•    The proportion of randomised participants initiated onto 
tuberculosis treatment on the same day as randomisa-
tion, with the numerator being participants who were 
initiated on tuberculosis treatment on Day 0, and the 
denominator being all randomised participants.
•    The proportion of randomised participants with undiag-
nosed/untreated microbiologically-confirmed pulmonary 
TB at Day 56, with the numerator being participants 
with microbiologically-confirmed tuberculosis (either 
sputum culture, or sputum Xpert, or sputum smear 
microscopy positive on a sample taken on Day 56) 
and who are confirmed not to be taking tuberculosis 
treatment on Day 56 (including participants who have 
previously initiated tuberculosis treatment, but have 
defaulted or stopped treatment – regardless of reason 
– for at least one week). The denominator will be 
all randomised participants.
•    The proportion of randomised participants with undi-
agnosed/untreated HIV at Day 56, with the numerator 
being participants with positive confirmatory HIV test 
results at Day 56 and who are not taking antiretroviral 
therapy (regardless of previous HIV test results during or 
before the study period), and the denominator being 
all randomised participants.
•    Time in days - from Day 0 up to but not including Day 
56 - to initiation of antiretroviral therapy among par-
ticipants with positive confirmatory HIV test results at 
Day 56 and who were not taking antiretroviral therapy at 
Day 0.
•    The proportion of randomised participants reported 
to have died by Day 56, with the numerator being 
participants confirmed to have died through home tracing 
visits or TB treatment records, and the denominator 
being all randomised participants
•    The proportion of TB cases with a successful TB treat-
ment outcome. The numerator will be participants 
who were initiated onto tuberculosis treatment (either 
microbiologically-confirmed or clinically-diagnosed tuber-
culosis) up to, but not including Day 56, and who have a 
successful TB treatment outcome (either cured or com-
pleted treatment) at 6-months after starting treatment. The 
denominator will be all participants confirmed to have 
initiated tuberculosis treatment between Day 0 and up to, 
but not including Day 56.
•    Mean difference in EuroQoL EQ5D utility score at 
Day 56, adjusting for participants’ EQ5D utility score 
measured at Day 0.
•    Mean difference in EuroQoL EQ5D visual analogue scale 
score, adjusting for participants’ EQ5D visual analogue 
scale score measured at Day 0.
•    Incremental cost-effectiveness per quality-adjusted life 
year gained
Planned subgroup analyses
In pre-planned exploratory analysis, we will stratify analysis of 
the primary outcome by: sex (male vs. female); and microbio-
logical status (bacteriologically-confirmed TB vs. clinically- 
diagnosed TB).
Additionally, we will undertake a Bayesian analysis of the 
primary trial outcome29. Prior distributions for the time to 
tuberculosis treatment under each intervention strategy will be 
elicited from key stakeholder groups. We anticipate that key 
stakeholders will include: community members; clinic health 
workers; researchers; TB/HIV experts; and policymakers 
(Malawi, regional, and international). Before eliciting stake-
holders’ prior beliefs for trial interventions, we will provide a 
series of “warm-up” vignettes based around familiar events such 
as the probability of a football team winning, or the probabil-
ity of it raining tomorrow. Each stakeholder will then be asked 
to make ten guesses for the percentage of participants who will 
initiated TB treatment under each intervention strategy.
Outcome evaluation
Following completion of trial interventions, all participants in 
each of the three groups will be given a written appointment 
card to attend a follow-up assessment at the study research clinic 
room 56 days after randomisation. They will also be issued 
with a voucher that they can use to reimburse the cost of trans-
port to the clinic for this assessment. Participants who don’t 
attend their day 56 appointment will be traced to home.
To evaluate the primary trial outcome (time to tuberculosis 
treatment initiation), we will undertake a detailed questionnaire 
to record the date of TB treatment initiation, and verify by 
inspecting participant-carried TB treatment cards, medication 
and clinic TB treatment registers.
To evaluate the prevalence of undiagnosed tuberculosis, we will 
collect sputa from all participants. Samples will be trans-
ported to the TB Research Laboratory at the College of Medi-
cine of Malawi, where they will be cultured for tuberculosis 
using the MGIT system, undergo smear examination using fluo-
rescence microscopy, and tested using the GeneXpert MTB/
Rif assay. Positive TB results will be reported to participants 
within three days of receipt (including by home tracing), and 
participants will be supported to register for TB treatment at the 
health facility.
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To evaluate the prevalence of undiagnosed HIV at Day 56, we 
will offer all participants HIV testing, unless they are confirmed 
to be taking antiretroviral therapy. All participants requiring 
additional care will be supported to access either the HIV clinic, 
TB clinic, or outpatient clinic at the study clinic as required. 
Additionally, we will support referral and access to Queen 
Elizabeth Central Hospital should further specialist care be 
required.
To evaluate health-related quality of life (HRQoL), we will 
use the EQ-5D-3L. The EQ-5D is a generic HRQoL measure, 
and was translated into Chichewa following international and 
EuroQoL guidelines. The EQ-5D-3L tool will be administered 
to all trial participants at baseline, and on Day 56.
Statistical methods
The primary trial outcome, time to TB treatment initiation, will 
be compared between pairs of groups among all randomised 
participants. To evaluate the relative effects of the HIV and TB 
screening/linkage interventions, we will make three pairwise 
comparison (Group 2 vs. Group 1; Group 3 vs Group 2; and 
Group 3 vs Group 1). Our pilot data show that 17% of adults with 
TB symptoms will initiate TB treatment under routine screening 
conditions within 8-weeks.
Using formula for the proportional hazards model developed 
by Schoenfield30, and inflating by 5% for loss to follow-up, a 
total sample size of 1455 participants (485 per group) gives at 
least 80% power to detect at least a cumulative hazard ratio for 
TB treatment initiation of 1.5 comparing Group 2 to Group 1, 
and a hazard ratio of 1.41 comparing Group 3 to Group 2, at 5% 
significance level. Additionally, under these assumptions, 485 
participants per group would give 80% power to detect a hazard 
ratio of at least 1.50 comparing Group 3 to Group 1.
All statistical analysis will be conducted in accordance with a 
pre-published statistical analysis plan (Supplementary File 2). 
Trial reporting will follow CONSORT Guidelines. We will 
report baseline characteristics of randomised participants, 
stratified by allocated group.
Analysis of the primary and secondary outcomes will be done 
on an intention to treat basis, with all participants allocated to 
trial groups included. We will index the day of recruitment to be 
Day 0 and outcome assessment will take place on, or as close 
to possible after, Day 56. Initiation of tuberculosis treatment 
will be defined by a participant in whom there is documented 
evidence of commencement of anti-tuberculosis treatment 
between Day 0 and up to, but not including Day 56. Time to 
TB treatment outcome analysis will be right-censored on day 
56 if TB treatment is not initiated. We will estimate per-group 
median times to TB treatment initiation, and plot cumulative 
hazard function graphs.
To investigate the relative effectiveness of interventions on the 
cumulative hazard of TB treatment initiation, we will conduct 
log rank tests and construct Cox proportional hazard regression 
models to estimate hazard ratios and 95% confidence 
intervals for each pairwise comparison (e.g. Group 2 vs. Group 1, 
Group 3 vs. Group 2, and Group 3 vs. Group 1). Log-log plots 
will be examined and Schoenfeld residuals used to test the 
proportional hazards assumption.
To analyse binary secondary outcomes (proportion with 
same-day tuberculosis treatment initiation, proportion with undi-
agnosed/untreated pulmonary tuberculosis, proportion with 
undiagnosed/untreated HIV, proportion reported to have died 
by Day 56, proportion with successful TB treatment outcome), 
we will construct log-binomial regression models to estimate 
relative risk ratios and 95% confidence intervals, comparing 
between pairs of groups. We will additionally compare between 
pairs of groups the time to antiretroviral therapy initiation 
among participants with previously untreated HIV using Cox 
regression models.
To evaluate the effect of interventions on health-related 
quality of life, we will use ANCOVA analysis to compare the 
mean EQ5D utility scores and visual analogue scale scores 
measured at Day 56 between pairs of groups, adjusting for 
participants’ values measured at Day 0.
For the preplanned subgroup analysis of the primary trial out-
come we will construct Cox proportion hazard regression 
models including a term for either sex (male or female) or 
microbiological TB status (either microbiologically confirmed 
or clinically-diagnosed) to estimate hazard ratios and 95% 
confidence intervals. We will use the likelihood ratio test to 
look for interactions between sex/microbiological-confirmed TB 
and trial group.
Bayesian analysis of primary trial outcome
Using within and between participant elicited probability 
distributions, we will construct stakeholder group-specific 
pooled prior probability distributions (known as a “commu-
nity of priors”). Each prior will be converted to a log-hazard 
ratio scale and fitted to a normal distribution, allowing compari-
son between stakeholder groups of the similarity in support of 
opinions of effectiveness and of uncertainty.
Using Bayes’ theorem, will combine elicited stakeholder group-
specific log hazard ratio prior distributions with log-likelihood 
hazard ratio distributions from each pairwise comparison 
being made in the PROSPECT Study to construct posterior 
probability distributions. All analysis will be done in R and 
posterior mean hazard ratios and 95% credible intervals will be 
estimated by taking draws from the posterior distributions 
using the No-U-Turn Sampler (NUTS) implemented with Stan.
Additional nested analysis
WHO has recommended that “Computer aided diagnosis 
can be used for TB detection for research, ideally following a 
protocol that contributes to the required evidence base for 
guideline development”22. The PROSPECT Study therefore 
offers opportunity to undertake a nested evaluation to contrib-
ute to the evidence base for the diagnostic accuracy (as well as 
effectiveness) of the CAD4TB platform.
Page 9 of 14
Wellcome Open Research 2018, 3:61 Last updated: 18 MAY 2018
Participants for this nested evaluation will be adults recruited 
to the main PROSPECT Study trial, and who complete a Day 
56 outcome TB screening assessment. As part of this outcome 
assessment, all participants will undergo CAD4TB classification 
of digital chest x-ray, as well as sputum testing by GeneXpert, 
and TB liquid automated culture. All digital chest x-rays taken 
from participants at outcome assessment will be uploaded to 
the password protected and secure MinXray online picture 
archiving and communication (PACS) radiology cloud server. 
All participant identifiers will be removed from x-rays prior to 
upload.
A panel of seven radiologists will each - independently and 
blinded to participant characteristics, HIV status, and results 
of microbiological investigations - classify chest x-rays using a 
standardised form for classification of chest radiology findings. 
Radiologists will review chest radiographs, and using an online 
data entry form, indicate the presence of any:
- Infiltrate or consolidation
- Cavitary lesion
- Nodule or mass with poorly defined margins
- Hilar/mediastinal adenopathy
- Pleural effusion
- Milliary findings
- Discrete linear opacity
- Discrete nodule(s) without calcification
- Other findings
Radiologists will additionally classify chest radiographs as 
either suggestive of active pulmonary tuberculosis, or not. We 
will use the kappa statistic (two outcomes, multiple readers) 
with 95% confidence intervals to assess inter-reader agreement 
among the radiologists.
For the diagnostic accuracy evaluation, the index test will be 
CAD4TB score (continuous variable ranging from 0 to 100, 
and in a secondary analysis, dichotomised for greater than 
or equal to the CAD4TB threshold score for high vs. low 
probability of tuberculosis, selected from pilot data and 
systematic analysis of previous CAD4TB diagnostic accuracy 
studies).
Reporting will follow the STARD Guidelines. For each index 
test definition (continuous distribution, and dichotomised to high 
vs. low probability of tuberculosis), we will compare diagnostic 
accuracy against two pre-defined reference standards:
1)    Consensus radiologist classification with at least 5/7 
independent readers agreeing that the radiograph was 
"suspicious of tuberculosis" (with sensitivity analy-
sis limited to cases only where all 7/7 readers were in 
agreement), and
2)    Bacteriologically-confirmed pulmonary tuberculo-
sis, defined as either a documented positive GeneXpert 
result for Mycobacterium tuberculosis on at least one 
sample of sputum taken for study purposes at Day 56 
assessment; or documented growth of Mycobacterium 
tuberculosis and positive specialisation using MPT 64 
antigen tests on at least one culture of sputum taken for 
study purposes at Day 56 assessment; or documented 
identification of acid fast bacilli on at least one sputum 
sample taken for study purposes and examined by 
sputum smear microscopy at Day 56 assessment.
For each comparison, sensitivity, specificity, positive predictive 
value, negative predictive value, and diagnostic odds ratios 
will be reported. Additionally, by constructing logistic regres-
sion models, we will investigate the effect of reader characteris-
tics on diagnostic accuracy with bacteriological-confirmation 
as the reference standard.
Validation of urinary lipoarabanimannan testing 
(LAM)
Urine LAM testing is a relatively new tuberculosis diagnos-
tic, that has high accuracy among adults with advanced HIV 
infection, and has been shown to reduce mortality in hospitalised 
HIV-positive adults9. The test is based on a lateral flow assay, 
and has been constructed to be used a point of care test, with 
results read at the bedside.
However, sensitivity is known to be suboptimal among ambu-
lant TB suspects. A newer version of the urine LAM test (FIND/
Fujifilm) has been reported to have high sensitivity for TB, 
even among ambulant adults, and HIV-negative individuals. 
Therefore, the PROSPECT Study offers opportunity to under-
take a nested evaluation of the performance of this test. We will 
collect a 5ml sample of urine from all participants at baseline, 
and transport the sample to the TB laboratory at the Col-
lege of Medicine of Malawi for urine LAM testing. We will 
compare the diagnostic yield of urine LAM testing with that of 
sputum culture, smear and Xpert from day 56 participant 
samples.
Data handling and management
Data will be collected by research assistants using the mobile 
CommCare data collection platform running on fingerprint 
secured tablets. Data will be transmitted to the secure study 
server over encrypted cellular networks. The MLW Data 
Department has considerable experience in building robust elec-
tronic data collection surveys and in secure data management, 
backup and processing. A full audit trial of database changes will 
be maintained.
Building upon our extensive experience of conducting pre-
vious trials using electronic data collection systems in 
Blantyre, the trial statistician and Chief Investigator will write 
scripts within the statistical programme R that will interface 
with the trial database and, on a regular automated basis, use 
logical rules to identify records with missing or implausible val-
ues that will be hand-checked against source records to ensure 
completeness and validity of the final dataset.
Page 10 of 14
Wellcome Open Research 2018, 3:61 Last updated: 18 MAY 2018
We are strongly committed to ensuring that the trial datasets 
are made openly available, and that all code used in the analy-
sis are published to allow fully reproducible research. The data 
collected by this research will be of importance to other research-
ers and the public, and could for example be used by other 
researchers conducting meta-analysis, or by policymakers 
modelling the potential return on investment of implementing 
interventions within their settings. Therefore, we will establish 
a public online GitHub repository, where the final anonymised 
individual- level trial dataset and code to allow reproduction of 
all analysis will be published. The availability of these resources 
will be publicised within academic manuscripts, through the 
MLW and LSTM websites.
Economic analysis
Two economic evaluations will be undertaken: firstly, a within-
trial evaluation; and secondly, a decision-analytic based cost 
effectiveness model. Both will be used to estimate the expected 
incremental cost per quality-adjusted life year (QALY) gained 
for the two optimized TB/HIV interventions in comparison to 
standard of care. For both analyses, the perspective will be that of 
the Malawi Ministry of Health, and will only include the direct 
medical costs.
The within trial evaluation will adopt a time horizon match-
ing the length of follow-up in the trial. The model-based 
evaluation will adopt a lifetime horizon so as to incorporate the 
long-term costs and health consequences of delayed TB/HIV 
diagnosis and treatment initiation.
As the distributions of costs and QALYs are commonly skewed, 
and often bimodal or truncated, a range of estimators will be 
explored and model diagnostics will be undertaken to determine 
optimal choice. Mean costs and outcomes for each intervention 
will be estimated, together with the mean incremental 
cost-effectiveness ratio. Measures of uncertainty (standard errors 
and confidence intervals) will also be reported for the mean 
estimates. In addition, net monetary benefits (NMBs) will be 
estimated for a range of different willingness to pay (WTP) 
thresholds. Based on the NMB framework, cost-effectiveness 
acceptability curves (CEACs) will be constructed to identify 
the optimal intervention at different WTP thresholds.
The model-based evaluation will aim to extrapolate trial 
findings to allow estimation of cost-effectiveness over a lifetime 
time horizon. The model will likely consist of mutually exclu-
sive Markov health states. These health states will be defined by 
a combination of untreated and treated states for both HIV and 
TB. The model will be parametrised by findings observed in 
the trial, and data extracted from the published literature.
Translating research into policy
Results of this research will be important in guiding national, 
regional and international health policy. WHO, policymakers 
and parliamentarians are currently grappling with how to 
improve access to TB and HIV diagnosis and treatment, includ-
ing the role of chest x-ray. A key objective of this study is 
therefore to translate research findings into normative guidance 
in Malawi, in sub-Saharan Africa, and through WHO.
We recognise that early engagement with policymakers is 
essential to translate research into action. Therefore, we 
undertaken preliminary scoping activities to identify key stake-
holders that we will work with, including Malawi Ministry 
of Health TB/HIV Technical Working Groups, the Malawi 
Network for Evidence-Informed Decision Making (EvIDeNt) 
which includes regional linkage through the African Institute for 
Development Policy (AFIDEP), and WHO TB-STAG.
Ethical considerations
This research has been approved by the College of Medicine 
of Malawi Research Ethics Committee (COMREC – number: 
P.11/17/2311), and the Research Ethics Committee of the 
Liverpool School of Tropical Medicine (number: 17-050). 
Trial progress will be reviewed by a data and safety monitoring 
board.
All prospective participants will be asked to provide written 
informed consent to take part in the trial. Individuals who are 
illiterate will be asked to provide a witnessed thumbprint to 
confirm their informed consent to participate. Witnesses will 
be an independent individual not involved with the study.
Timelines
Piloting and preparatory activities will commence in April 
2018, and trial recruitment in June 2018. We anticipate recruit-
ing participants over a 15-month period, with final outcome 
assessment of treatment outcomes and mortality conducted 
after 6-months. Thus, the study will be completed in July 2020.
Trial registration
This trial was registered with ClinicalTrials.gov on the 8th May 
2018 (NCT03519425).
Discussion
The PROSPECT Study will use a pragmatic trial design31 to 
evaluate optimised TB/HIV screening and treatment linkage 
interventions under “real-life” condition in primary care in 
Malawi. The three-arm design allows us to efficiently test two 
important hypotheses.
Firstly, by comparing Group 2 to Group 1, we will investigate 
whether HIV care should be prioritised for adults with symp-
toms of TB. In previous studies, we and others have found 
operationalising universal HIV testing for adults attending pri-
mary care challenging due to limited counsellor capacity8, 
meaning that only individuals in whom clinicians had a high 
suspicion of HIV were referred to the counsellor for HIV 
testing32. Implementing a semi-supervised HIV self-testing 
intervention could then free-up counsellor capacity, increasing 
testing coverage. Moreover, self-testing is popular with patients, 
as it allows them to take control of the manner in which they 
learn their HIV status25,33. In addition to ensuring that individuals 
with TB symptoms are not “caught” between the HIV and 
TB care clinics16, facilitated linkage to HIV care may pro-
mote earlier, more intensive screening for TB than would have 
otherwise occurred in the general outpatient clinic. Initiation of 
antiretroviral therapy may also unmask TB in individuals with 
advanced immunosuppression34, prompting an earlier clinical 
decision to initiate tuberculosis treatment.
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By comparing Group 3 to Group 2 and Group 1, we will provide 
strong evidence on the effectiveness of a novel triage approach 
to TB screening. As no single TB diagnostic currently has 
optimal characteristics in terms of test accuracy, reliability, 
implementation and scalability at primary care level, and cost 
per case detected, a triage approach that comprises an effi-
cient, high sensitivity initial test, followed by a high specificity 
confirmatory test is required for patients with symptoms of 
TB. WHO recently undertook a modelling exercise to compare 
potential triage testing approaches, and found that, among 
adults with TB symptoms, an algorithm comprised of an initial 
chest x-ray followed by a confirmatory GeneXpert MTB/Rif 
test would likely fulfil requirements of having a high overall 
sensitivity and specificity, low number needed to screen to 
detect a case, and low cost per case detected22. Moreover, this 
approach is attractive as, with the increasing availability of 
affordable digital x-ray units, the entire triage algorithm can be 
completed on the same day and within the same clinic. As an 
initial screening tool, chest x-ray can be performed quickly 
for large numbers of cases, screening out those with a low 
probability of disease. However, until now, widespread imple-
mentation has been limited by cost and by the availability 
of trained radiologists to classify x-rays. Therefore, in this 
study, we will evaluate the effectiveness of the CAD4TB 
computer aided diagnosis software system as the chest x-ray 
reader, which has demonstrated high accuracy (comparable to 
radiologists and clinicians) in diagnostic accuracy studies in 
Europe and Africa23. In a nested evaluation, we will examine 
the diagnostic accuracy of the CAD4TB system compared 
to a panel of radiologists and sputum culture for Mycobacterium 
tuberculosis.
There are some limitations to this study. Although we will take 
extensive steps to minimise contamination between groups, includ-
ing by participant fingerprint validation prior to intervention 
delivery, undertaking the trial in a single primary health may 
influence routine care decisions made by clinicians. Should 
evidence for effectiveness of these interventions be found, 
further supportive evidence would be provided by a future 
trial that randomly allocated clinics to intervention groups, 
and by surveillance of key process indicators under routine 
implementation conditions. The primary trial outcome will 
compare the time to TB treatment initiation between groups, an 
important indicator of individual and public health effective-
ness. However, future larger studies may wish to investigate 
effectiveness against mortality, here investigated as a secondary 
outcome. Finally, as a sputum sample for TB culture will not be 
taken from participants in all groups at baseline, we will 
not be able to estimate the effectiveness of interventions on 
participants with true microbiologically-confirmed disease. This 
was a deliberate design of the study; TB culture is not widely-
available in Africa as standard of care, meaning that empirical 
TB treatment is common35. Should we have offered participants 
TB culture of sputum at baseline, we would not be able to 
obtain a true estimate of the effectiveness of interventions 
under “real-life” conditions. To ensure all participants are 
provided with high-quality screening and care, at Day 56 
they will all be offered TB and HIV screening and supported 
to access care.
An important component of the PROSPECT Study is the evalu-
ation of effects on patient-important outcomes – as measured by 
change in health-related quality of life – and cost-effectiveness. 
In Blantyre, we have well-established systems for patient 
and health resource costing36, and will use both a within-trial 
cost-effectiveness evaluation, as well as a decision-analytic 
based cost effectiveness model. Additionally, we will work 
through the Policy Unit at the Malawi-Liverpool-Wellcome 
Trust Clinical Programme to engage early with national TB and 
HIV programmes in Malawi, and with regional and suprana-
tional policy fora. The exploratory Bayesian trial analysis will 
incorporate the prior beliefs of various groups of stakeholders 
to ensure that meaningful evidence can be provided to key 
groups.
Dissemination of findings
Trial results and findings from the cost-effectiveness analysis 
will be shared with Blantyre District Health Office, the Malawi 
National Tuberculosis Programme and with the Malawi National 
HIV Programme. We will report findings at national, regional 
and international conferences, and will submit a manuscript 
reporting trial findings to a peer-reviewed journal specialising 
in public health, HIV and tuberculosis.
To facilitate reproducibility of analysis, an anonymised minimal 
final dataset and all code required to reproduce analysis 
will be published in the trial GitHub repository.
Current trial status
The trial is currently in preparatory and piloting phase.
In summary, the PROSPECT Study will provide urgently-needed 
evidence under “real-life” conditions to inform clinicians 
and policy makers on how best to improve TB/HIV diagnosis 
and treatment initiation in Africa.
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